Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study
International Journal of Clinical Oncology · 2026-08 · 31 (8) · 1658-1667
DOI: 10.1007/s10147-026-03075-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 11.06.2026. Verfasst von Koichi Sugimoto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kindai University Faculty of Medicine, 3-1-14 Mihara-dai, Minami-ku, Sakai City, 589-8511, Osaka, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitor (ICI)-based combination therapies, including immune checkpoint inhibitor plus immune checkpoint inhibitor (IO + IO) and immune checkpoint inhibitor plus tyrosine kinase inhibitor (IO + TKI) regimens, have significantly improved outcomes in metastatic renal cell carcinoma (mRCC). However, the prognostic impact of host-related factors in patients receiving these therapies remains unclear.
Methods
We retrospectively analyzed 493 patients with mRCC treated with IO+IO ( n = 205) or IO+TKI ( n = 288) as first-line therapy. Survival outcomes and treatment responses were evaluated according to host-related factors using Cox proportional hazards models.
Results
In the IO+IO cohort, multiple host-related factors were independently associated with worse overall survival, including BMI < 25 kg/m 2 (HR 2.280, p = 0.007), dyslipidemia (HR 2.079, p = 0.019), PPI use (HR 1.605, p = 0.039), and opioid use (HR 2.919, p = 0.008). In contrast, in the IO+TKI cohort, only IMDC poor risk (HR 4.169, p < 0.001) and opioid use (HR 3.328, p < 0.001) were significantly associated with overall survival. Host-related factors showed limited associations with objective response and disease control rates in both cohorts.
Conclusion
The prognostic impact of host-related factors differs according to treatment regimen in mRCC. These findings suggest that host immune and metabolic conditions play a more prominent role in immune-driven IO+IO therapy, whereas tumor-related factors may predominate in IO+TKI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kindai University Faculty of Medicine, 3-1-14 Mihara-dai, Minami-ku, Sakai City, 589-8511, Osaka, Japan.
- Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
- Department of Urology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
- Department of Urology, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Zitieren
APA
Sugimoto, K., Toyoda, S., Inoki, L., Mori, K., Yanagisawa, T., Tamura, K., Nukaya, T., Maenosono, R., Morinaka, H., Nishimura, S., Bekku, K., Komura, K., Takahara, K., Inamoto, T., Azuma, H., Fujita, K., & JK-FOOT study group (2026). Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study. International Journal of Clinical Oncology, 31(8), 1658-1667. https://doi.org/10.1007/s10147-026-03075-2
Vancouver
Sugimoto K, Toyoda S, Inoki L, Mori K, Yanagisawa T, Tamura K, et al. Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study. International Journal of Clinical Oncology. 2026;31(8):1658-1667. doi:10.1007/s10147-026-03075-2
BibTeX
@article{Sugimoto2026,
author = {Sugimoto, Koichi and Toyoda, Shingo and Inoki, Lan and Mori, Keiichiro and Yanagisawa, Takafumi and Tamura, Keita and Nukaya, Takuhisa and Maenosono, Ryoichi and Morinaka, Hirofumi and Nishimura, Shingo and Bekku, Kensuke and Komura, Kazumasa and Takahara, Kiyoshi and Inamoto, Teruo and Azuma, Haruhito and Fujita, Kazutoshi and JK-FOOT study group, JK-FOOT study group},
title = {Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {8},
pages = {1658--1667},
doi = {10.1007/s10147-026-03075-2}
}
EUVIMED